CK2 inhibitor 3 is a highly potent inhibitor of protein kinase CK2, exhibiting an IC50 value of 280 nM. It effectively inhibits the intracellular activity of CK2 and displays a notable impact on the viability of tumor cells. Moreover, CK2 inhibitor 3 demonstrates exceptional selectivity among a diverse panel of 320 kinases [1].

CK2 inhibitor 3 (compound 4) significantly reduces cell viability in Jurkat cells in a dose-dependent manner, with a DC50 value of 12.80 μM after 24 hours at concentrations from 0 to 50 μM [1]. Additionally, at 5 μM and 20 μM over 16 hours, it reduces CK2-dependent phospho-site Akt Ser129 levels, demonstrating targeted efficacy [1].